Home Tags Mythic Therapeutics

Tag: Mythic Therapeutics

Preclinical Data Highlights the Differentiating Properties of MYTX-011

Preclinical data highlighting the differentiating properties of Mythic Therapeutics' investigational cMET-targeting antibody-drug conjugates (ADC), MYTX-011, published in April 30, 2024 edition of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), demonstrated that this novel ADC which leverages Mythic’s innovative FateControl™ technology, actively navigated inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells.

What to Expect at ASCO ’23: Mythic Therapeutics’ MYTX-011 Trial In...

During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...

Gilles Gallant, BPharm, PhD, FOPQ, Receives the 2022 George R. Pettit...

Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer, at Mythic Therapeutics has received the George R. Pettit Individual Input to the Field Award for 2022.  The award was presented at the 13th World ADC Conference, held in San Diego, CA, during the 9th World ADC Awards Ceremony held on Thursday, September 8, 2022.

X